Update shared on 11 Nov 2025
Analysts have raised their price target for Fevertree Drinks to £9.29. This update reflects revised discount rate assumptions along with modest refinements to growth and profitability forecasts.
What's in the News
- The Directors of Fevertree Drinks PLC declared an interim dividend of 5.97 pence per share, a 2% increase from the 2024 interim dividend. The payout is scheduled for 17 October 2025 to shareholders registered as of 26 September 2025. (Company announcement)
- Fevertree Drinks PLC will host a Special/Extraordinary Shareholders Meeting on 17 October 2025 at the office of Reynolds Porter Chamberlain LLP in London, United Kingdom. (Company announcement)
- The company completed the repurchase of 6,776,859 shares, representing 5.81% of shares, for £53.6 million. This buyback occurred between January 30, 2025 and June 30, 2025, fulfilling the plan announced earlier in the year. (Company announcement)
Valuation Changes
- Consensus Analyst Price Target remains unchanged at £9.29 per share.
- Discount Rate has risen slightly, increasing from 6.82% to 7.07%.
- Revenue Growth forecasts show no material change and are holding steady at approximately 11.26%.
- Net Profit Margin estimate is virtually flat and remains near 11.10%.
- Future P/E ratio has increased modestly from 31.16x to 31.38x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.